YAP phosphorylation and activation of the sphingolipid metabolic enzyme SGPP2 jointly mediate tumor metabolic adaptation (51); whilst the sphingolipid metabolic enzyme CERK promotes drug resistance in ER+ BC (52–54). This evidence concerns the gene SGPP2 and neoplasm.